source
- FDA launches rare disease framework initiativeA new initiative from the US Food and Drug Administration (FDA) aims to develop “an optimized, fit-for-purpose” framework to facilitate the development and marketing of treatments for rare diseases…raps · 6d ago↗ source
- Gilead invests up to $1.87 B in Vir Biotechnology for three T-cell engagersGilead Sciences announced a licensing agreement with Vir Biotechnology that includes an equity investment and potential milestone payments totalling up to $1.87 billion. The upfront component is $…